FDA says OK to leave FreeStyle Libre CGMs on for imaging
By HME News Staff
Updated 9:19 AM CDT, Wed October 30, 2024
ABBOTT PARK, Ill. – Users of the FreeStyle Libre 2 and 3 continuous glucose monitoring systems from Abbott no longer need to remove and discard the devices for imaging procedures, such as X-rays, CT scans and MRIs. The U.S. Food and Drug Administration has cleared the removal of the imaging contraindication, making Abbott’s systems the first and only patient-applied CGM sensors approved for these screenings. "For people with diabetes, especially those using insulin, removing a CGM sensor for long periods can be problematic," said Carol Wysham, M.D., clinical professor of medicine at the University of Washington School of Medicine and section head of the department of diabetes and endocrinology at Rockwood Clinic in Spokane. "Previously, patients had to remove their sensors during these procedures, resulting in several hours without critical data, especially if they didn’t have a replacement sensor. The removal of the imaging contraindication from Abbott’s FreeStyle Libre 2 and 3 systems is a big win for patients, allowing them to keep their sensors on and avoid lost data."
Comments